Lung Cancer

The benefits of adagrasib over docetaxel were seen regardless of baseline brain metastases, according to findings presented at ESMO.

Zipalertinib demonstrates safety and efficacy in heavily pretreated patients with NSCLC EGFR exon 20 insertion mutations who progressed on or after amivantamab.

The combination of encorafenib and binimetinib showed anti-tumor responses in treatment-naïve BRAF V600E-mutant advanced non–small cell lung cancer.

A lower dose of pembrolizumab may be as effective as the standard dose for treating stage IV non-small cell lung cancer.

The novel ALK inhibitor NVL-655 demonstrated encouraging activity in heavily pretreated patients with advanced ALK-positive NSCLC.

Nicolas Girard, MD, discusses the RELATIVITY-104 trial of nivolumab plus relatlimab and chemotherapy in previously untreated stage IV or recurrent NSCLC.

Amivantamab plus chemotherapy yielded promising OS trends compared with chemotherapy in EGFR-mutant advanced NSCLC after disease progression on osimertinib.

Treatment with belrestotug plus dostarlimab yielded a clinically meaningful improvement in ORR vs dostarlimab monotherapy in unresectable PD-L1–high NSCLC.

BMS-986012 plus nivolumab and chemotherapy provided a modest PFS benefit but signals of OS improvement in extensive-stage small cell lung cancer.

Consistent survival benefit was seen with consolidation durvalumab across subgroups in the ADRIATIC trial affirms its use as a standard of care in LS-SCLC.

Adjuvant durvalumab did not provide a disease-free survival advantage over placebo in patients with NSCLC across different PD-L1 subgroups.

The FDA has approved subcutaneous atezolizumab for use in all indications as the intravenous formulation.

The DUBLIN-3 trial showed plinabulin plus docetaxel improved survival in EGFR wild-type non–small cell lung cancer.

Experts from across oncology specialties discuss the abstracts and presentations they are most looking forward to seeing at the 2024 ESMO Congress.

T. Jeroen N. Hiltermann, MD, discusses findings from phase 1/2 ARTEMIDE-01 trial.

Patients with EGFR-mutated NSCLC demonstrated reduced symptom progression when treated with amivantamab plus lazertinib vs osimertinib.

T-DXd showed clinical activity regarding responses and survival outcomes in patients with pretreated HER2-overexpressed metastatic non–small cell lung cancer.

Benjamin Besse, MD, PhD, discusses findings from the phase 3 CARMEN-LC03 trial.

Luis Raez, MD, highlights considerations with phases of treatment in lung cancer, detailing factors affecting use of adjuvant therapy when a patient has a complete response.

Tusamitamab ravtansine vs docetaxel was not significantly different regarding survival in patients with advanced nonsquamous non–small cell lung cancer.

Neoadjuvant durvalumab plus chemotherapy and adjuvant durvalumab improves event-free survival in stage IIA-IIIB resectable non–small cell lung cancer vs. placebo.

Xiuning Le, MD, PhD, discusses updated findings from the phase 1/2 SOHO-01 trial.

The safety profile of adjuvant alectinib was tolerable and manageable in ALK-positive NSCLC.

Tarlatamab demonstrated durable responses and long-term tolerability in patients with previously treated small cell lung cancer.

Rilvegostomig induced responses with acceptable tolerability in patients with checkpoint inhibitor-naive, metastatic NSCLC.